For DFI, high-expressed HOXC10 increased the risk of poor prognosis in LGG, LUAD, and ACC but decreased the risk of poor prognosis in KIRP, UCS, PCPG, and BLCA (Figure 1D). This evidence concerns the gene HOXC10 and bladder transitional cell carcinoma.